Curriculum Vitae

Personal information

Sergio Todde

Work experience

1. Employer: Tecnomed, Foundation of the University of Milano_Bicocca
   - Start date: 112010
   - End date:
   - Position: Director
   - Activities: Management, organization of a University Foundation
   - Country: Italy
2. Employer: University of Milano_Bicocca; Tecnomed, Foundation of the University of Milano_Bicocca, Via Pergolesi 33, 20052 Monza
   - Start date: 092009
   - End date:
   - Position: Senior Investigator _ Head of Radiopharmacy
   - Activities: Synthesis, development and quality control of radiopharmaceuticals labelled with positron emitting isotopes
     _ Responsible of quality assurance system dedicated to the production of PET radiopharmaceuticals in agreement with Italian and European guidelines
     _ Teaching and tutorial activity at the University of Milano_Bicocca. Teaching and tutorial activity at the University of Ferrara. Teaching and tutorial activity at the University of Pavia
   - Country: Italy
3. Employer: University of Milano_Bicocca, c/o Cyclotron/PET Centre of Scientific Institute Hospital San Raffaele, Via Olgettina 60, 20132, Milano
   - Start date: 042002
   - End date: 082009
   - Position: Senior Investigator
   - Activities: Synthesis, development and quality control of radiopharmaceuticals labelled with positron emitting isotopes
     _ Supervisor of the two cyclotrons hosted by the Facility, namely RDS Eclipse RD and IBA Cyclone 18/9
     _ Implementation of quality assurance system dedicated to the production of PET radiopharmaceuticals
     _ Teaching and tutorial activity at the University of Milano_Bicocca. Teaching and tutorial activity at the University of Ferrara. Teaching and tutorial activity at the University of Pavia
   - Country: Italy
4. Employer: University of Milano_Bicocca, c/o Cyclotron/PET Centre of Scientific Institute Hospital San Raffaele, Via Olgettina 60, 20132, Milano
   - Start date: 012000
   - End date: 042002
   - Position: Investigator
   - Activities: Synthesis, development and quality control of radiopharmaceuticals labelled with positron emitting isotopes
     _ Supervisor of the two cyclotrons hosted by the Facility, namely RDS Eclipse RD and IBA Cyclone 18/9
   - Country: Italy
5. Employer: Kernforschunganlage, Institut fuer Nuklearchemie. D_52425 Juelich, Germany
   - Start date: 051992
   - End date: 101992
   - Position: Fellow Investigator
   - Activities: Automated production of C_11 labelled radiopharmaceuticals
   - Country: Germany
6. Employer: University of Milano, c/o Cyclotron/PET Centre of the Scientific Institute Hospital San Raffaele, Via Olgettina 60, 20132, Milano
   - Start date: 101989
   - End date: 121999
   - Position: Investigator
   - Activities: Synthesis, development and quality control of radiopharmaceuticals labelled with positron emitting isotopes
   - Country: Italy

Education and training

1. Subject: University of Milano
   - Start date: 111980
   - End date: 101987
   - Qualification: Degree in Biology
   - Organisation:
   - Country: Italy

Additional information

Publications

n. 52 articles published by peer reviewed international scientific journals editor of a book on radiochemistry

- Magni F, Casati R, Todde S, Colombo F, Fazio F, and Galli Kienle M. Sensitive GC-MS method for the determination of specific-activity of 16β[^{18}F]Fluoro-estra-1,3,5(10)-triene-3,17b-diol. Appl Radiat Isot, 1992; 43: 1299-1300.

- Moresco RM, Casati R, Lucignani G, Carpinelli A, Schmidt K, Todde S, Colombo F, and Fazio F. Systemic and cerebral kinetics of 16β[^{18}F]fluoro-17-b-estradiol: a ligand for the in vivo assessment of estrogen receptor parameters. J Cerebr Blood F Met, 1995; 15: 301-311.

- Cappa SF, Perani D, Grassi F, Bressi S, Alberoni M, Franceschi M, Bettinardi V, Todde S, and Fazio F. A PET follow-up study of recovery after stroke in acute aphasics. Brain Lang, 1997; 56: 55-67.4.

- Matarrese M, Soloviev D, Todde S, Magni F, Colombo F, Galli Kienle M, and Fazio F. Synthesis of [O-methyl-^{11}C]fluvoxamine - a potential serotonin uptake Uptake Site Radioligand. Appl. Radiat. Isot. 1997; 48:749-754

- Matarrese M, Soloviev D, Moresco RM, Ferri V, Simonelli P, Magni F, Colombo D, Todde S, Carpinelli A, Fazio F and Galli Kienle M. Synthesis and Biodistribution of (R,S)-[O-methyl-11C]-1-[3-(5-methoxy-1,2,3,4-tetrahydro-1-naphtalenyl)propyl]-4-phenylpiperazine (PNU-157760), A Putative Radioligand for 5-HT1A Receptors. Bioorganic Chemistry 1998; 26:91-102

- Angelini G, Carnevaletti F, Margonelli A, Corsi G, Ragni P, Fazio F, Todde S, Tinti O. Mild synthesis of [N-methyl-^{11}C]-isovaleroyl-(L)-carnitine. The usefulness of a tritium approach. Appl. Radiat. Isot. 1999; 50:303-309.

- Studenov AR, Berridge MS, Soloviev DV, Matarrese, Todde S. High yield synthesis of [11C]-Acetone through selective quenching of methyl lithium. Nucl. Med. Biol. 1999; 26: 431-435

- Matarrese M, Soloviev D, Moresco RM, Todde S, Simonelli P, Colombo D, Magni F, Carpinelli A, Fazio F, Galli Kienle M. Synthesis and in vivo evaluation of 3-[^{11}C]methyl-(3-methoxy-naphthalen)-2-yl-(1-benzyl-piperidin)-4-yl-acetate (SB-235753), as a putative dopamine D_4 receptor antagonist for PET. J. Labelled Cpd. Radiopharm. 2000; 43: 359-374

- Todde S, Moresco RM, Froestl W, Stampf P, Matarrese M, Carpinelli A, Magni F, Galli Kienle M, Fazio F. Synthesis and in vivo evaluation of [^{11}C]CGP62349, a new $GABA_B$ receptor antagonist. Nucl. Med. Biol. 2000; 27(6): 565-569

- Moresco RM, Matarrese M, Soloviev D, Simonelli P, Rigamonti M, Gobbo C, Todde S, Carpinelli A, Galli Kienle M, Fazio F. Synthesis and in vivo evaluation of [^{11}C]ICI118551 as a putative subtype selective β-adrenergic radioligan. Int. J. Pharm. 2000; 204: 101-109

- Todde S, Moresco RM, Simonelli P, Baraldi PG, Cacciari B, Spalluto G, Varani K, Monopoli A, Matarrese M, Carpinelli A, Magni F, Galli Kienle M, Fazio F. Design, radiosynthesis and biodistribution of a new potent and selective ligand for the in vivo imaging of adenosine A_{2A} receptor system using positron emitting tomography. J. Med. Chem. 2000; 43: 4359-4362

- Soloviev D, Matarrese M, Moresco RM, Todde S, Bonasera T, Sudati F, Simonelli P, Magni F, Colombo D, Carpinelli A, Galli Kienle M, Fazio F. Asymmetric synthesis and preliminary evaluation of (R)- and (S)-[^{11}C]bisoprolol, a putative β-selective adrenoceptor radioligand. Neurochem. Int. 2001; 38: 169-180

- Carpinelli A, Matarrese M, Moresco RM, Simonelli P, Todde S, Magni F, Galli Kienle M, Fazio F. Radiosynthesis of [^{123}I]βCIT, a selective ligand for the study of dopaminergic and serotononergic system in human brain. Appl. Radiat. Isot. 2001; 54: 93-86

- Moresco RM, Messa C, Lucignani G, Rizzo G, Todde S, Gilardi MC, Grimaldi A, Fazio F. PET in Psychopharmacolgy. Pharmacol. Res. 2001, Sep 44(3):151-9

- Matarrese M, Moresco RM, Cappelli A, Anzini M, Vomero S, Simonelli P, Verza E, Magni F, Sudati F, Soloviev D, Todde S, Carpinelli A, Galli Kienle M, Fazio F. Labeling and evaluation of N-[11C]methylated quinoline-2-carboxamides as potential radioligands for visualization of peripheral benzodiazepine receptors. J. Med. Chem. 2001, 44:579-585

- Matarrese M, Sudati F, Soloviev D, Todde S, Turolla EA, Galli Kienle M, Fazio F. Automation of [^{11}C]acyl chloride syntheses using commercially available ^{11}C- modules. Appl. Radiat. Isot. 2002, 57:675-679

- Matarrese M, Moresco RM, Romeo G, Turolla EA, Simonelli P, Todde S, Belloli S, Carpinelli A, Magni F, Russo F, Galli Kienle M, Fazio F. [11C]RN5: a new agent for the in vivo imaging of myocardial alpha1-adrenoceptors. Eur J Pharmacol. 2002, 453(2-3):231-238

- Matarrese M, Soloviev D, Todde S, Neutro F, Petta P, Carpinelli A, Brussermann M, Galli Kienle M, Fazio F. Preparation of [^{11}C]radioligands with high specific activity on a commercial PET tracer synthesizer. Nucl. Med. Biol. 2003; 30: 79-83

- Matarrese M, Salimbeni A, Turolla EA, Turozzi D, Moresco RM, Poma D, Magni F, Todde S, Rossetti C, Sciarrone MT, Bianchi G, Galli Kienle M, Fazio F. ^{11}C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [^{11}C]zofenoprilat. Bioorg. Med. Chem. 2004, 12: 603-611

- Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, Galli-Kienle M, Fazio F. In vivo imaging of adenosine A(2A) receptors in rat and primate brain using [(11)C]SCH442416. Eur J Nucl Med Mol Imaging. 2005, 32(4): 405-413

- Turolla EA, Matarrese M, Belloli S, Moresco RM, Simonelli P, Todde S, Fazio F, Magni F, Galli Kienle M, Leopoldo M, Berardi F, Colabufo NA, Lacivita E, Perrone R. ^{11}C-labeling of N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide derivatives and evaluations as potential radioligands for PET imaging of dopamine D_3 receptors. J.Med.Chem. 2005,48: 7018-7023

- Carpinelli A, Magni F, Cattaneo A, Matarrese M, Turolla E, Todde S, Galli Kienle M, Fazio F. Improved synthesis and radiolabelling of [^{11}C]MP4A, a suitable ligand for the investigation of the cholinergic system using PET. Appl. Radiat. Isot. 64 (2006) 182–186

- Calandrino R, Del Vecchio A, Savi A, Todde S, Griffoni V, Brambilla S, Parisi R, Simone G, Fazio F. Decommissioning procedures for an 11 MeV self-shielded medical cyclotron after 16 years of working time. Health Phys, 2006; 90 (6): 588-596.

- Calandrino R, Del Vecchio A, Todde S, Fazio F. Measurement and Control of the Air Contamination Generated in a Medical Cyclotron Facility for PET Radiopharmaceuticals. Health Phys. 2007; 92 (2): 70-77

- Filannino MA, Matarrese M, Turolla EA, Masiello V, Moresco RM, Todde S, Verza E, Magni F, Cattaneo A, Bachi A, Galli Kienle M, Fazio F. Synthesis and C-11 labelling of (R) and (S)-thionisoxetine, norephineprine reuptake inhibitors, potential radioligand for positron emission tomography. Appl. Radiat. Isot. 2007; 65: 1232-1239.

- Ottobrini L, Ciana P, Moresco RM, Lecchi M, Belloli S, Martelli C, Todde S, Fazio F, Gambhir SS, Maggia A, Lucignani G. Development of a bicistronic vector for multimodality imaging of estrogen receptor activity in a breast cancer model: preliminary Application. Eur. J. Nucl. Med. Mol. Imaging. 2008; 35:365-378

- Moresco RM, Lavazza T, Belloli S, Lecchi M, Pezzoli A, Todde S, Matarrese M, Carpinelli A, Turolla EA, Zimarino V, Popoli P, Malgaroli A, Fazio F. Quinolinic acid induced neurodegeneration in the striatum: a combined in vitro and in vivo analysis of receptor changes and microglia activation. Eur. J. Nucl. Med. Mol. Imaging. 2008; 35: 704-715

- Calandrino R, Del Vecchio A, Savi A, Todde S, Belloli S. Intake risk and dose evaluation methods for workers in radiochemistry

labs of a medical cyclotron facility. Health Phys. 2009; 97 (4): 315-321

- Calandrino R, Del Vecchio A, Parisi R, Todde S, De Felice P, Savi A, Pepe A, Mrskova A. Measurement and evaluation of the risk due to external radiation exposure and to intake of activated elements for operational staff engaged in the maintenance of medical cyclotrons. Radiation Protection Dosimetry. 2010; 139(4): 477-482

- Matarrese M, Bedeschi P, Scardaoni R, Sudati F, Savi A, Pepe A, Masiello V, Todde S, Gianolli L, Messa C, Fazio F. Automated production of copper radioisotopes and preparation of high specific activity [^{64}Cu]Cu-ATSM for PET studies. Appl. Radiat. Isot. 2010; 68: 5-13

- Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre-Chauvet A, Mikolajczak R, Westera G, Gmeiner-Stopar T, Decristoforo C. Guidance on Current Good Radiopharmacy Practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging. 2010; 37: 1049-1062

- Crivellaro C, Signorelli M, Guerra L, De Ponti E, Buda A, Dolci, C, Pirovano C, Todde S, Fruscio R, Messa C. 18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecologic Oncology. 2012; 127: 131-135

- Aerts J, Ballinger JR, Behe M, Decristoforo C, Elsinga PH, Faivre-Chauvet A, Mindt TL, Kolenc Peitl P, Todde SC, Koziorowski J. Guidance on current good radiopharmacypractice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective. J. Label Compd. Radiopharm. 2014. 57: 615-620

- Todde S, Windhorst AD, Behe M, Bormans G, Decristoforo C, Faivre-Chauvet A, Ferrari V, Gee AD, Gulyas B, Halldin C, Kolenc Peitl P, Koziorowski J, Mindt TL, Sollini M, Vercouillie J, Ballinger JR, Elsinga PH. EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD). Eur. J. Nuc. Med. Mol. Imaging. 2014; 41: 2175-2185

- Curtarello M, Zulato E, Nardo G, Valtorta S, Guzzo G, Rossi E, Esposito G, Msaki A, Pastò A, Rasola A, Persano L, Ciccarese F, Bertorelle R, Todde S, Plebani M, Schroer H, Walenta S, Mueller-Klieser W, Amadori A, Moresco RM, Indraccolo S. VEGF targeted therapy stably modulates the glycolytic phenotype of tumor cells. Cancer Research. 2015; January (1), 75:120-133

- Koziorowski J, Behe M, Decristoforo C, Ballinger J, Elsinga P, Ferrari V, Kolenc Peitl P, Todde S, Mindt T.L. Position paper on

requirements for toxicological studies in the specific case of radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry. 2016; 1: 1.

- Gaglio D, Valtorta S, Ripamonti M, Bonanomi M, Damiani C, Todde S, Negri AS, Sanvito F, Mastroianni F, Di Campli A, Turacchio G, Di Grigoli G, Belloli S, Luini A, Gilardi MC, Colangelo AM, Alberghina L, Moresco RM.Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: A PET imaging and metabolomics-mass-spectrometry study. ONCOTARGET, 2016, 7(32), 52017-52031

- Decristoforo C, Penuelas I, Patt M, Todde S. European regulation for the introduction of novel radiopharmaceuticals in the clinical setting. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2017, 61(2): 135-144

- Todde S, Kolenc Peitl, Elsinga P, Koziorowski J, Ferrari V, Ocak EM, Hjelstuen O, Patt M, Mindt TL, Behe M. Guidance on validation and qualification of processes and operations involving radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry. 2017; 2:8

- Lugato B, Stucchi S, Ciceri S, Iannone MN, Turolla EA, Giuliano L, Chinello C, Todde S, Ferraboschi P. A novel versatile precursor suitable for ^{18}F-radiolabeling via “click chemistry” J. Label Compd Radiopharm. 2017; 60: 466-480.

- Turolla EA, Valtorta S, Bresciani E, Fehrentz JA, Giuliano L, Stucchi S, Belloli S, Rainone P, Sudati F, Rizzi L, Molteni L, Verdiè P, Martinez J, Torsello A, Moresco R, Todde S. Study of the tissue distribution of TLQP-21 in mice using [^{18}F]JMV5763, a radiolabeled analog prepared via [^{18}F]Aluminum Fluoride chelation chemistry. Frontiers in Pharmacology. 2018. doi: 10.3389/fphar.2018.01274, 9, article 1274.

- Crivellaro C, De Ponti E, Elisei F, Morzenti S, Picchio M, Bettinardi V, Versari A, Fioroni F, Dziuk M, Tkaczewski K, Ahond-Vionnet R, Nodari G, Todde S, Landoni C, Guerra L. Added diagnostic value of respiratory gated 4D 18F-FDG PET/CT in the detection of liver lesions: a multicenter study. Eur. J. Nucl. Med. Mol. Imaging 2018. 45(1):102-109.

- Dolci C, Spadavecchia C, Crivellaro C, De Ponti E, Todde S, Morzenti S, Turolla EA, Crespi A, Guerra L, Landoni C. Treatment response assessment in [18F]FDG-PET/CT oncology scans: impact of count statistics variation and reconstruction protocols. Physica Medica. 2019; 57: 177-182

- Gillings N, Todde S, Behe M, Decristoforo C, Elsinga P, Ferrari V, Hjelstuen O, Kolenc Peitl P, Koziorowski J, Laverman P, Mindt TL, Ocak M and Patt M. EANM Guideline on the validation of

analytical methods for radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry. 2020. 5:7, https://doi.org/10.1186/s41181-019-0086-z.

- Gillings N, Hjelstuen O, Ballinger J, Behe M, Decristoforo C, Elsinga P, Ferrari V, Kolenc Peitl P, Koziorowski J, Laverman P, Mindt TL, Neels O, Ocak M, Patt M, Todde S. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparations of radiopharmaceuticals. EJNMMI Radiopharmacy and Radiochemistry. 2021; 6:8, https://doi.org/10.1186/s41181-021-00123-2

- Valtorta S, Lo Dico A, Raccagni I, Martelli C, Pieri V, Rainone P, Todde S, Zinnhardt B, De Bernardi E, Coliva A, Politi LS, Viel T, Jacobs AH, Galli R, Ottobrini L, Vaira V, Moresco RM. Imaging metformin efficacyas add-on therapy in cellsand mouse models of human EFGR glioblastoma. Frontiers in Oncology. 2021; 11: article 664149; doi: 10.3389/fonc.2021.664149

- S. Boschi, S. Todde. From radiotracer to radiopharmaceutical: a philosophical approach. EJNMMI. 2021. https://doi.org/10.1007/s00259-021-05588-6

- Iannone MN, Stucchi S, Turolla EA, Beretta C, Ciceri S, Chinello C, Pagani L, Todde S, Ferraboschi P. Synthesis and automated fluorine-18 radiolabeling of new PSMA-617 derivatives with a CuAAC radiosynthetic approach. J. Labelled Compd Radiopharm. 2022; 65: 48-62. DOI: 10.1002/jlcr.3959.

- De Ponti E, Crivellaro C, Morzenti S, Monaco L, Todde S, Landoni C, Elisei F, Musarra M, Guerra L. Clinical Application of high sensitivity BGO PET/CT scanner: effects of acquisition protocols and reconstruction parameters on lesion quantification. Current Radiopharmaceuticals. 2022, doi: 10.2174/1874471015666220107100200

- Gillings N, Hjelstuen O, Behe M, Decristoforo C, Elsinga PH, Ferrari V, Kiss OC, Kolenc P, Koziorowski J, Laverman P, Mindt TL, Ocak M, Patt M, Todde S, Walte A. EANM guideline on risk management for radiopharmaceuticals. EJNMMI. 2022; https://doi.org/10.1007/s00259-022-05738-4

- Korde A, Mikolajczak R, Kolenc P, Bouziotis P, Westin H, Lauritzen M, Koole M, Herth MM, Bardies M, Martins AF, Paulo A, Lyashchenko SK, Todde S, Nag S, Lamprou E, Abrunhosa A, Giammarile F, Decristoforo C. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals. EJMMI Radiopharmacy and Chemistry. 2022; 7:18, https://doi.org/10.1186/s41181-022-00168-x

- Boschi S, Todde S. PET radiopharmacy and automation. Nuclear Medicine and Molecular Imaging. 2022 (1); 227-234.

Projects

- development of new PET radiopharmaceuticals
- development of new targets for radionuclide production

Memberships

- Member of the Italian Group of Radiopharmaceutical Chemistry (GICR)
- Member of the Italian Medicine Agency (AIFA) working group on Radiopharmaceuticals
- Member of the European Association of Nuclear Medicine

Other Relevant Information

Collaboration with the International Atomic Energy Agency (IAEA) and World Health Organization (WHO)